News & Events

Shanghai, China, December 10, 2024 – Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced that it has signed agreement with Bayer.

Epigenic Therapeutics today announced that it has received approval of CTA from the New Zealand Medicines and Medsafe and HDEC to initiate a clinical trial for EPI-003, which is an investigational, liver-targeting antiviral therapy for CHB virus infection.

Shanghai, China, 26 October 2024- Epigenic Therapeutics announced acceptance of an oral presentation at the AASLD to be held in San Diego, California, 15-19 November 2024. The presentation is entitled “Robust and sustainable elimination of HBsAg by epigenome modulation enables seroconversion of chronic HBV infection in HBV mouse model”.

Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.

Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J